<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02104505</url>
  </required_header>
  <id_info>
    <org_study_id>13-1605</org_study_id>
    <secondary_id>R01ES023349</secondary_id>
    <nct_id>NCT02104505</nct_id>
  </id_info>
  <brief_title>Effect of Gamma Tocopherol Enriched Supplementation on Response to Inhaled LPS</brief_title>
  <acronym>Vitalps</acronym>
  <official_title>Effect of Gamma Tocopherol Enriched Supplementation on Response to Inhaled LPS</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of North Carolina, Chapel Hill</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Institute of Environmental Health Sciences (NIEHS)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
    <collaborator>
      <agency>Purdue University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University of North Carolina, Chapel Hill</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      To test the hypothesis that gamma tocopherol (vitamin E) supplement inhibits endotoxin&#xD;
      induced airways inflammation in allergic asthmatics&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      BACKGROUND:&#xD;
&#xD;
      Allergic asthma (AA) is the most commonly encountered respiratory disease in children and&#xD;
      adults in the United States and is a leading cause of morbidity worldwide. Among the most&#xD;
      disruptive expressions of disease in AA is acute asthma exacerbation. The Center for Disease&#xD;
      Control lists ambient air pollutants and environmental tobacco smoke as among the most common&#xD;
      triggers for acute asthma exacerbation. Ozone (O3) is the most commonly encountered ambient&#xD;
      air pollutant in the US. Endotoxin (or lipopolysaccharide or LPS) is a component of&#xD;
      bioaerosols found in both the indoor and outdoor environment, is a component of tobacco&#xD;
      smoke, and is increased in indoor settings where smokers live. LPS is also a component of&#xD;
      coarse and fine mode particle matter air pollution.&#xD;
&#xD;
      OXIDATIVE STRESS AND ASTHMA:&#xD;
&#xD;
      Increased oxidative stress and decreased antioxidant capability have been observed in&#xD;
      asthmatics. These pollutants are pro-inflammatory and are associated with increased oxidative&#xD;
      stress, which would exacerbate reactive oxygen and reactive nitrogen species (ROS and&#xD;
      RNS)-induced injury in asthmatics. O3 injures epithelial cells, releasing secondary mediators&#xD;
      which activate inflammatory cells, in part by ligation of Toll-Like Receptor 4 (TLR4), the&#xD;
      primary receptor for LPS. TLR4 activation of inflammatory cells activates Nuclear Factor-kB&#xD;
      (NF-kB) and induces oxidative stress. O3 and LPS has been associated with exacerbation of&#xD;
      asthma, and we have reported that O3 and LPS augments allergic airway inflammation in&#xD;
      allergic asthmatics (AA). Development of interventions to mitigate these responses will&#xD;
      greatly decrease disease morbidity.&#xD;
&#xD;
      Given the role that oxidants play in the pathophysiology of asthma exacerbation, defects in&#xD;
      antioxidant levels would increase risk for acute asthma exacerbation. Nutritional&#xD;
      deficiencies in vitamin E, ascorbate and selenium have been linked to asthma severity, and&#xD;
      asthmatics have decreased antioxidant levels in airway fluid. We and others have shown that&#xD;
      vitamins C and E are decreased in airway fluids of asthmatics. Additionally, genetic factors&#xD;
      may increase risk for oxidant induced exacerbation of asthma. Many investigators have&#xD;
      reported that persons who are homozygous for the null polymorphism of the&#xD;
      Glutathione-S-Transferase Mu1 (GSTM1) gene and unable to produce GSTM1 protein (the GSTM1&#xD;
      null genotype) have increased risk of acute pollutant-induced exacerbation of asthma. We have&#xD;
      shown in healthy volunteers that the GSTM1 null genotype is associated with increased&#xD;
      inflammatory response to O3, with no impact on the nociceptive response to this pollutant. We&#xD;
      have also shown that GSTM1 null volunteers have enhanced airway and systemic inflammation&#xD;
      following LPS challenge.&#xD;
&#xD;
      Others have shown that the GSTM1 null genotype is associated with increased response to&#xD;
      secondhand tobacco smoke, diesel exhaust, and other particulate matter components. Romieu et&#xD;
      al demonstrated that children with asthma in Mexico City were had increases susceptibility to&#xD;
      O3-induced exacerbations if they had the GSTM1 null genotype. This group also found that&#xD;
      GSTM1 null AAs selectively benefited from antioxidant intervention. The GSTM1 null genotype&#xD;
      is found in 20-40% of the population, and may be overrepresented in allergic populations.&#xD;
      Taken together, these observations show that the sizable GSTM1 null population is at risk for&#xD;
      pollutant-induced airway disease, and that antioxidant intervention targeting the action of&#xD;
      ROS and RNS will benefit asthmatics and especially GSTM1 null asthmatics.&#xD;
&#xD;
      ANTIOXIDANTS AND ASTHMA:&#xD;
&#xD;
      A non-exclusive list of proposed antioxidants includes radical scavengers such as ascorbate,&#xD;
      a-tocopherol (aT), y-tocopherol (yT) or inducers of the antioxidant gene response element&#xD;
      transcription factor NRF2, which activate NRF2 with subsequent broad upregulation of acute&#xD;
      phase II and antioxidant proteins. These agents are available in naturally occurring foods&#xD;
      and as nutritional supplements. A number of animal, cell culture and epidemiological studies&#xD;
      support the idea that antioxidant supplementation is useful in allergic airway disease.&#xD;
      However, despite these studies and widespread public and scientific enthusiasm regarding use&#xD;
      of such agents in asthmatics, there are scant human data to support or refute the use of such&#xD;
      interventions for either acute or chronic allergic airways disease. It is crucial that&#xD;
      adequate, well-designed human studies assess the role of antioxidants for allergic asthma to&#xD;
      either confirm their efficacy, or refute claims that these are effective, safe and low cost&#xD;
      interventions for allergic disease.&#xD;
&#xD;
      GAMMA TOCOPHEROL AND ASTHMA:&#xD;
&#xD;
      Gamma tocopherol has both radical scavenging and anti-inflammatory actions which may play&#xD;
      important roles in decreasing pollutant-induced and allergic injury to the airway.&#xD;
&#xD;
      Like other isoforms of vitamin E, yT is a potent ROS scavenger and is also a powerful&#xD;
      nucleophile that traps electrophiles such as peroxynitrite in lipophilic compartments. One&#xD;
      mechanism by which y-T is cytoprotective is scavenging of RNS at the un-substituted C-5&#xD;
      position on the hydroxy-chroman ring of y-T to form 5-NO-y-tocopherol (5-NO-yT). Overall,&#xD;
      vitamin E provides general protection of DNA, lipids and proteins from radical stress. An&#xD;
      example of such protection is shown in rodent studies of prostate cancer in which intake of&#xD;
      yT is associated with decreased DNA methylation of CpG rich regions of the NRF2. NRF2 is a&#xD;
      master regulator of numerous cytoprotective antioxidant enzymes.&#xD;
&#xD;
      Supplementation with yT also prevents protein nitration and attenuates loss of plasma vitamin&#xD;
      C in plasma in a rodent peritonitis model of inflammation. Our group has also shown that yT&#xD;
      inhibits cyclo-oxygenase-2 (COX-2) and 5-lipoxygenase (5-LO) in LPS-stimulated macrophages&#xD;
      and interleukin (IL)-1b stimulated epithelial cells. These actions are mediated primarily by&#xD;
      the yT metabolite 2, 7, 8-trimethyl-2S-(.-carboxyethyl)-6-hydroxychroman (y-CEHC) which&#xD;
      requires hydroxylation of the y-methyl group of yT by cytochrome P450 (CYP450). In&#xD;
      carrageenan- induced inflammation in male Wistar rats, yT decreases prostaglandin (PGE2) and&#xD;
      leukotriene (LTB4) production, suggesting that 5-LO-mediated production of leukotrienes may&#xD;
      also be inhibited by yT. Tocopherols, including yT, also modulate gene expression of a number&#xD;
      of inflammatory genes. Thus, yT and other tocopherols decrease production of a number of&#xD;
      pro-inflammatory cytokines at the transcriptional level.&#xD;
&#xD;
      In animals, we have also shown that gamma tocopherol reduces baseline eosinophilia in the&#xD;
      airway. In our early phase I studies of gamma tocopherol-enriched mixed tocopherols (gT-mT)&#xD;
      we have shown that gT-mT inhibits monocyte induced cytokine production, decreases baseline&#xD;
      nitrosative stress, and inhibits LPS eosinophil and neutrophil influx in healthy volunteers.&#xD;
&#xD;
      SUMMARY:&#xD;
&#xD;
      There is widespread opinion that antioxidant nutrients like gamma tocopherol ( yT, a form of&#xD;
      Vitamin E) are an untapped and inexpensive intervention for environmentally triggered acute&#xD;
      asthma. However, there is a crucial gap in evidence-based support of such interventions in&#xD;
      asthma. A lack of coordinated research assessing specific antioxidant regimens from&#xD;
      preclinical, phase I and phase II studies impedes development of phase III antioxidant trials&#xD;
      in asthmatic populations. It is also unclear which physiological endpoints are most relevant&#xD;
      in such studies. This project focuses on phase II studies of yT in AA based on our&#xD;
      preclinical and phase I studies. For this protocol we will be testing the hypothesis that a&#xD;
      gamma tocopherol supplement will baseline eosinophil numbers in airway sputa of asthmatics&#xD;
      (specific aims 1) and (specific aim 2) inhibit LPS induced airway inflammation in mild&#xD;
      allergic asthmatics.&#xD;
&#xD;
      The investigators will also do an exploratory assessment of the specific impact of the GSTM1&#xD;
      null genotype on response to LPS and effect of gamma tocopherol enriched supplementation on&#xD;
      this response.&#xD;
&#xD;
      If gamma tocopherol decreases LPS-induced response in asthmatics, this would provide proof of&#xD;
      concept that this agent would be a useful intervention for asthma, confirming teh need for a&#xD;
      phase III study of gamma tocopherol enriched supplements as a treatment for asthma.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">November 2015</start_date>
  <completion_date type="Actual">August 2017</completion_date>
  <primary_completion_date type="Actual">September 2016</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Comparison of Change in Sputum Percent Neutrophils (PMN)s Following Inhaled Clinical Center Reference Endotoxin (CCRE) Challenge as Affected by Gamma Tocopherol</measure>
    <time_frame>after 14 days of gamma tocopherol or placebo treatment</time_frame>
    <description>In asthmatic individuals, exposure to CCRE is expected to increase PMNs in the sputum. The sputum PMNs were measured at baseline (immediately prior to dosing) and again on day 14 of treatment (approximately 8 hours after the final dose) with placebo or gamma tocopherol. The outcome is to compare the change in PMNs from baseline to post treatment after exposure to CCRE</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Chronic Eosinophilic Airway Inflammation as Affected by Gamma Tocopherol</measure>
    <time_frame>after 14 days of gamma tocopherol or placebo treatment</time_frame>
    <description>The sputum eosinophils were measured at baseline (immediately prior to dosing) and again after 14 days of treatment (approximately 8 hours after the final dose) with placebo or gamma tocopherol. The outcome is to compare sputum eosinophils per mg before and after gamma tocopherol treatment.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mucociliary Clearance (MCC) Associated With CCRE Challenge as Affected by Gamma Tocopherol</measure>
    <time_frame>after 14 days of gamma tocopherol or placebo treatment</time_frame>
    <description>On day 14 of treatment (approximately 6 hours after the final dose) with placebo or gamma tocopherol, a whole lung region of interest (ROI) bordering the right lung was used to estimate (by computer analysis) whole lung retention of inhaled radiolabeled particles. This was performed by measuring the labeled particle counts over a 2 hour period and determining the fraction of initial particle counts remaining. From this data, we determined the percentage of labeled particles cleared from the lung during the 2 hour observation period.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mucociliary Clearance as Affected by Gamma Tocopherol</measure>
    <time_frame>after 11 days of gamma tocopherol or placebo treatment</time_frame>
    <description>On day 11 of treatment (approximately 6 hours after the daily dose) with placebo or gamma tocopherol, a whole lung region of interest (ROI) bordering the right lung was used to estimate (by computer analysis) whole lung retention of inhaled radiolabeled particles. This was performed by measuring the labeled particle counts over a 2 hour period and determining the fraction of initial particle counts remaining. From this data, we determined the percentage of labeled particles cleared from the lung during the 2 hour observation period.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">23</enrollment>
  <condition>Mild, Allergic Asthma</condition>
  <arm_group>
    <arm_group_label>700 mg Gamma Tocopherol daily x 14days</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Gamma Tocopherol supplement</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Safflower oil capsules</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Gamma Tocopherol 700 mg capsules,</intervention_name>
    <description>2 capsules daily</description>
    <arm_group_label>700 mg Gamma Tocopherol daily x 14days</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Safflower oil capsules</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Age 18-50 of both genders&#xD;
&#xD;
          2. Negative pregnancy test for females who are not s/p hysterectomy with oophorectomy&#xD;
&#xD;
          3. History of episodic wheezing, chest tightness, or shortness of breath consistent with&#xD;
             asthma, or physician diagnosed asthma.&#xD;
&#xD;
          4. Positive methacholine test. A positive test is defined as a provocative concentration&#xD;
             of methacholine of 10 mg/ml or less producing a 20% fall in Forced Expiratory Volume&#xD;
             in 1 second (FEV1) (PC20 methacholine) by the method used in a separate screening&#xD;
             protocol.&#xD;
&#xD;
          5. FEV1 of at least 80% of predicted and FEV1/FVC ratio of at least .70 (without use of&#xD;
             bronchodilating medications for 12 hours or long acting beta agonists for 24 hours),&#xD;
             consistent with lung function of persons with no more than mild episodic or mild&#xD;
             persistent asthma.&#xD;
&#xD;
          6. Allergic sensitization to at least one of the following allergen preparations: (House&#xD;
             Dust Mite f, House dust mite p, Cockroach, Tree mix, Grass Mix, Weed Mix, Mold Mix 1,&#xD;
             Mold Mix 2, Rat, Mouse, Guinea Pig, Rabbit, Cat or Dog) confirmed by positive&#xD;
             immediate skin test response.&#xD;
&#xD;
          7. Symptom Score (this will be submitted as an attachment) no greater than 16 (out of a&#xD;
             possible 24) for total symptom score with a value no greater than 3 for any one score.&#xD;
             No more than one score may be greater or equal than 3.&#xD;
&#xD;
          8. subjects must be willing to avoid caffeine for 12 hours prior to all visits.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Any chronic medical condition considered by the PI as a contraindication to the&#xD;
             exposure study including significant cardiovascular disease, diabetes, chronic renal&#xD;
             disease, chronic thyroid disease, history of chronic infections/immunodeficiency,&#xD;
             history of tuberculosis&#xD;
&#xD;
          2. Physician directed emergency treatment for an asthma exacerbation within the preceding&#xD;
             12 months&#xD;
&#xD;
          3. Moderate or Severe asthma&#xD;
&#xD;
          4. Exacerbation of asthma more than 2x/week which would be characteristic of a person of&#xD;
             moderate or severe persistent asthma as outlined in the current NHLBI guidelines for&#xD;
             diagnosis and management of asthma.&#xD;
&#xD;
          5. Daily requirement for albuterol due to asthma symptoms (cough, wheeze, chest&#xD;
             tightness) which would be characteristic of a person of moderate or severe persistent&#xD;
             asthma as outlined in the current National Heart, Lung and Blood Institute (NHLBI)&#xD;
             guidelines for diagnosis and management of asthma. (Not to include prophylactic use of&#xD;
             albuterol prior to exercise).&#xD;
&#xD;
          6. Viral upper respiratory tract infection within 2 weeks of challenge.&#xD;
&#xD;
          7. Any acute infection requiring antibiotics within 2 weeks of exposure or fever of&#xD;
             unknown origin within 2 weeks of challenge.&#xD;
&#xD;
          8. Severe asthma&#xD;
&#xD;
          9. Mental illness or history of drug or alcohol abuse that, in the opinion of the&#xD;
             investigator, would interfere with the participant's ability to comply with study&#xD;
             requirements.&#xD;
&#xD;
         10. Medications which may impact the results of the Clinical Center Reference Endotoxin&#xD;
             (CCRE) exposure, interfere with any other medications potentially used in the study&#xD;
             (to include steroids, beta antagonists, non-steroidal anti-inflammatory agents)&#xD;
&#xD;
         11. Any history of smoking in the year prior to study enrollment; lifetime smoking history&#xD;
             &gt; 10 pack years&#xD;
&#xD;
         12. Nighttime symptoms of cough or wheeze greater than 1x/week at baseline (not during a&#xD;
             clearly recognized viral induced asthma exacerbation) which would be characteristic of&#xD;
             a person of moderate or severe persistent asthma as outlined in the current NHLBI&#xD;
             guidelines for diagnosis and management of asthma&#xD;
&#xD;
         13. Allergy/sensitivity to study drugs, including E coli, or their formulations.&#xD;
&#xD;
         14. Known hypersensitivity to methacholine or to other parasympathomimetic agents&#xD;
&#xD;
         15. History of intubation for asthma&#xD;
&#xD;
         16. Unwillingness to use reliable contraception if sexually active (Intrauterine device,&#xD;
             birth control pills/patch, condoms).&#xD;
&#xD;
         17. Abnormal Prothrombin Time (PT) or Partial Thromboplastin Time (PTT) values at&#xD;
             screening or during the treatment period. Normal values will be those published by the&#xD;
             clinical lab (Labcorp, INC).&#xD;
&#xD;
         18. Any bleeding disorder&#xD;
&#xD;
         19. Radiation exposure history will be collected. Subjects whose exposure history within&#xD;
             the past twelve months would cause them to exceed their annual limits will be&#xD;
             excluded.&#xD;
&#xD;
         20. Pregnancy&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>50 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>David B Peden, MD, MS</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of North Carolina, Chapel Hill</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Center for Environmental Medicine, Asthma and Lung Biology</name>
      <address>
        <city>Chapel Hill</city>
        <state>North Carolina</state>
        <zip>27599</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>September 2017</verification_date>
  <study_first_submitted>March 24, 2014</study_first_submitted>
  <study_first_submitted_qc>April 1, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 4, 2014</study_first_posted>
  <results_first_submitted>September 6, 2017</results_first_submitted>
  <results_first_submitted_qc>October 4, 2017</results_first_submitted_qc>
  <results_first_posted type="Actual">November 6, 2017</results_first_posted>
  <last_update_submitted>October 4, 2017</last_update_submitted>
  <last_update_submitted_qc>October 4, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">November 6, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Tocopherols</mesh_term>
    <mesh_term>Vitamin E</mesh_term>
    <mesh_term>Tocotrienols</mesh_term>
    <mesh_term>alpha-Tocopherol</mesh_term>
    <mesh_term>gamma-Tocopherol</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <pre_assignment_details>There was no wash out or run-in phase prior to treatment assignment. No enrolled participants were excluded prior to treatment assignment.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Gamma Tocopherol (14 Days) Then Placebo (14 Days)</title>
          <description>Gamma Tocopherol (2 capsules, each containing 700 mg, daily) x 14 days, washout for minimum 3 weeks, then Safflower oil capsules x 14 days</description>
        </group>
        <group group_id="P2">
          <title>Placebo (14 Days) Then Gamma Tocopherol (14 Days)</title>
          <description>Safflower oil capsules x 14 days, washout for minimum 3 weeks, then Gamma Tocopherol (2 capsules, each containing 700 mg, daily) x 14 days</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>First Intervention (14 Days)</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="12"/>
                <participants group_id="P2" count="11">one participant withdrew prior to receiving study drug</participants>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="10"/>
                <participants group_id="P2" count="8"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="3"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>exclusionary condition</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
        <period>
          <title>Washout (Minimum 3 Weeks)</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="10"/>
                <participants group_id="P2" count="8"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="10"/>
                <participants group_id="P2" count="8"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
        <period>
          <title>Second Intervention (14 Days)</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="10"/>
                <participants group_id="P2" count="8"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="8"/>
                <participants group_id="P2" count="7"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Gamma Tocopherol (14 Days) Then Placebo (14 Days)</title>
          <description>Gamma Tocopherol (2 capsules, each containing 700 mg, daily) x 14 days, washout for minimum 3 weeks, then Safflower oil capsules x 14 days</description>
        </group>
        <group group_id="B2">
          <title>Placebo (14 Days) Then Gamma Tocopherol (14 Days)</title>
          <description>Safflower oil capsules x 14 days, washout for minimum 3 weeks, then Gamma Tocopherol (2 capsules, each containing 700 mg, daily) x 14 days</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="12"/>
            <count group_id="B2" value="11"/>
            <count group_id="B3" value="23"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="12"/>
                    <measurement group_id="B2" value="11"/>
                    <measurement group_id="B3" value="23"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="23.5" lower_limit="20" upper_limit="42"/>
                    <measurement group_id="B2" value="30" lower_limit="21" upper_limit="47"/>
                    <measurement group_id="B3" value="26" lower_limit="20" upper_limit="47"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="10"/>
                    <measurement group_id="B2" value="9"/>
                    <measurement group_id="B3" value="19"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="11"/>
                    <measurement group_id="B2" value="11"/>
                    <measurement group_id="B3" value="22"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="2"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="2"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="4"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="8"/>
                    <measurement group_id="B2" value="7"/>
                    <measurement group_id="B3" value="15"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="12"/>
                    <measurement group_id="B2" value="11"/>
                    <measurement group_id="B3" value="23"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Atopy</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="9"/>
                    <measurement group_id="B2" value="8"/>
                    <measurement group_id="B3" value="17"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Body Mass Index (BMI)</title>
          <units>kg/m2</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="27.1" lower_limit="20.5" upper_limit="34.8"/>
                    <measurement group_id="B2" value="25.2" lower_limit="20.2" upper_limit="41.7"/>
                    <measurement group_id="B3" value="26" lower_limit="20.2" upper_limit="41.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Forced expiratory volume in 1 second (FEV1) (%predicted)</title>
          <units>percent predicted</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="102.5" lower_limit="89" upper_limit="109"/>
                    <measurement group_id="B2" value="90" lower_limit="83" upper_limit="108"/>
                    <measurement group_id="B3" value="97" lower_limit="83" upper_limit="109"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Comparison of Change in Sputum Percent Neutrophils (PMN)s Following Inhaled Clinical Center Reference Endotoxin (CCRE) Challenge as Affected by Gamma Tocopherol</title>
        <description>In asthmatic individuals, exposure to CCRE is expected to increase PMNs in the sputum. The sputum PMNs were measured at baseline (immediately prior to dosing) and again on day 14 of treatment (approximately 8 hours after the final dose) with placebo or gamma tocopherol. The outcome is to compare the change in PMNs from baseline to post treatment after exposure to CCRE</description>
        <time_frame>after 14 days of gamma tocopherol or placebo treatment</time_frame>
        <population>Since this study employed a crossover design, only participants who completed both arms of the study were included in the analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>Gamma Tocopherol</title>
            <description>Gamma Tocopherol 700 mg capsules,: 2 capsules daily for 14 days</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>700 mg Safflower oil capsules; 2 capsules daily for 14 days</description>
          </group>
        </group_list>
        <measure>
          <title>Comparison of Change in Sputum Percent Neutrophils (PMN)s Following Inhaled Clinical Center Reference Endotoxin (CCRE) Challenge as Affected by Gamma Tocopherol</title>
          <description>In asthmatic individuals, exposure to CCRE is expected to increase PMNs in the sputum. The sputum PMNs were measured at baseline (immediately prior to dosing) and again on day 14 of treatment (approximately 8 hours after the final dose) with placebo or gamma tocopherol. The outcome is to compare the change in PMNs from baseline to post treatment after exposure to CCRE</description>
          <population>Since this study employed a crossover design, only participants who completed both arms of the study were included in the analysis.</population>
          <units>change in percentage of PMNs in sputum</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="15"/>
                <count group_id="O2" value="15"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11.7" spread="20.7"/>
                    <measurement group_id="O2" value="20.1" spread="16.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.04</p_value>
            <method>Mixed Models Analysis</method>
            <param_type>Mean Difference (Net)</param_type>
            <param_value>0.41</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.18</dispersion_value>
            <ci_n_sides>2-Sided</ci_n_sides>
            <estimate_desc>Comparison of change in sputum %PMNs during active treatment vs placebo (crossover design).</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Chronic Eosinophilic Airway Inflammation as Affected by Gamma Tocopherol</title>
        <description>The sputum eosinophils were measured at baseline (immediately prior to dosing) and again after 14 days of treatment (approximately 8 hours after the final dose) with placebo or gamma tocopherol. The outcome is to compare sputum eosinophils per mg before and after gamma tocopherol treatment.</description>
        <time_frame>after 14 days of gamma tocopherol or placebo treatment</time_frame>
        <population>Since this study employs a crossover design, only participants who completed both arms of the study were included in the final analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>Gamma Tocopherol</title>
            <description>Gamma Tocopherol 700 mg capsules,: 2 capsules daily for 14 days</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>700 mg Safflower oil capsules; 2 capsules daily for 14 days</description>
          </group>
        </group_list>
        <measure>
          <title>Chronic Eosinophilic Airway Inflammation as Affected by Gamma Tocopherol</title>
          <description>The sputum eosinophils were measured at baseline (immediately prior to dosing) and again after 14 days of treatment (approximately 8 hours after the final dose) with placebo or gamma tocopherol. The outcome is to compare sputum eosinophils per mg before and after gamma tocopherol treatment.</description>
          <population>Since this study employs a crossover design, only participants who completed both arms of the study were included in the final analysis.</population>
          <units>eosinophils per mg sputum</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="15"/>
                <count group_id="O2" value="15"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.6" spread="4.3"/>
                    <measurement group_id="O2" value="9.5" spread="14.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.01</p_value>
            <method>Mixed Models Analysis</method>
            <param_type>Mean Difference (Net)</param_type>
            <param_value>0.64</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.22</dispersion_value>
            <ci_n_sides>2-Sided</ci_n_sides>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mucociliary Clearance (MCC) Associated With CCRE Challenge as Affected by Gamma Tocopherol</title>
        <description>On day 14 of treatment (approximately 6 hours after the final dose) with placebo or gamma tocopherol, a whole lung region of interest (ROI) bordering the right lung was used to estimate (by computer analysis) whole lung retention of inhaled radiolabeled particles. This was performed by measuring the labeled particle counts over a 2 hour period and determining the fraction of initial particle counts remaining. From this data, we determined the percentage of labeled particles cleared from the lung during the 2 hour observation period.</description>
        <time_frame>after 14 days of gamma tocopherol or placebo treatment</time_frame>
        <population>Due to the crossover design of the study, only participants who completed both arms of the study were included in the analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>Gamma Tocopherol</title>
            <description>Gamma Tocopherol 700 mg capsules: 2 capsules daily for 14 days</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>700 mg Safflower oil capsules; 2 capsules daily for 14 days</description>
          </group>
        </group_list>
        <measure>
          <title>Mucociliary Clearance (MCC) Associated With CCRE Challenge as Affected by Gamma Tocopherol</title>
          <description>On day 14 of treatment (approximately 6 hours after the final dose) with placebo or gamma tocopherol, a whole lung region of interest (ROI) bordering the right lung was used to estimate (by computer analysis) whole lung retention of inhaled radiolabeled particles. This was performed by measuring the labeled particle counts over a 2 hour period and determining the fraction of initial particle counts remaining. From this data, we determined the percentage of labeled particles cleared from the lung during the 2 hour observation period.</description>
          <population>Due to the crossover design of the study, only participants who completed both arms of the study were included in the analysis.</population>
          <units>% of labeled particles cleared from lung</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="15"/>
                <count group_id="O2" value="15"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="20.2" spread="8"/>
                    <measurement group_id="O2" value="16.3" spread="9.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.6</p_value>
            <method>Mixed Models Analysis</method>
            <param_type>Mean Difference (Net)</param_type>
            <param_value>-0.32</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.33</dispersion_value>
            <ci_n_sides>2-Sided</ci_n_sides>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mucociliary Clearance as Affected by Gamma Tocopherol</title>
        <description>On day 11 of treatment (approximately 6 hours after the daily dose) with placebo or gamma tocopherol, a whole lung region of interest (ROI) bordering the right lung was used to estimate (by computer analysis) whole lung retention of inhaled radiolabeled particles. This was performed by measuring the labeled particle counts over a 2 hour period and determining the fraction of initial particle counts remaining. From this data, we determined the percentage of labeled particles cleared from the lung during the 2 hour observation period.</description>
        <time_frame>after 11 days of gamma tocopherol or placebo treatment</time_frame>
        <population>Due to the crossover study design, only participants who completed both arms of the study were included in the analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>Gamma Tocopherol</title>
            <description>Gamma Tocopherol 700 mg capsules,: 2 capsules daily for 14 days</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>700 mg Safflower oil capsules; 2 capsules daily for 14 days</description>
          </group>
        </group_list>
        <measure>
          <title>Mucociliary Clearance as Affected by Gamma Tocopherol</title>
          <description>On day 11 of treatment (approximately 6 hours after the daily dose) with placebo or gamma tocopherol, a whole lung region of interest (ROI) bordering the right lung was used to estimate (by computer analysis) whole lung retention of inhaled radiolabeled particles. This was performed by measuring the labeled particle counts over a 2 hour period and determining the fraction of initial particle counts remaining. From this data, we determined the percentage of labeled particles cleared from the lung during the 2 hour observation period.</description>
          <population>Due to the crossover study design, only participants who completed both arms of the study were included in the analysis.</population>
          <units>% of labeled particles cleared from lung</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="15"/>
                <count group_id="O2" value="15"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="21.4" spread="9.7"/>
                    <measurement group_id="O2" value="21.4" spread="6.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.34</p_value>
            <method>Mixed Models Analysis</method>
            <param_type>Mean Difference (Net)</param_type>
            <param_value>-0.32</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.33</dispersion_value>
            <ci_n_sides>2-Sided</ci_n_sides>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>3 months on average</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Gamma Tocopherol</title>
          <description>Gamma Tocopherol 700 mg capsules; 2 capsules daily for 14 days</description>
        </group>
        <group group_id="E2">
          <title>Placebo</title>
          <description>700 mg Safflower oil capsules; 2 capsules daily for 14 days</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="20"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="11" subjects_at_risk="17"/>
                <counts group_id="E2" subjects_affected="14" subjects_at_risk="20"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Vagal response</sub_title>
                <assessment>Non-systematic Assessment</assessment>
                <description>nausea, lightheadedness, pallor during phlebotomy</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="17"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="20"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Diminished sense of taste</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" events="6" subjects_affected="6" subjects_at_risk="17"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="17"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Diarrhea</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="17"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Abdominal bloating</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="17"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Heartburn</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Loose stools</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="17"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Loss of appetite</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="17"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Flatulence</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="17"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Stomach cramps</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="20"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="17"/>
                <counts group_id="E2" events="2" subjects_affected="1" subjects_at_risk="20"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Urinary tract infection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="20"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Cough during CCRE challenge</sub_title>
                <assessment>Non-systematic Assessment</assessment>
                <description>Cough observed during CCRE challenge</description>
                <counts group_id="E1" events="7" subjects_affected="7" subjects_at_risk="17"/>
                <counts group_id="E2" events="6" subjects_affected="6" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Wheezing</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="17"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Shortness of breath</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="17"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Cough during sputum induction</sub_title>
                <assessment>Non-systematic Assessment</assessment>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="17"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Shortness of breath during sputum induction</sub_title>
                <assessment>Non-systematic Assessment</assessment>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Chest tightness</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="17"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Cough</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Nasal congestion</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="20"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Skin redness</sub_title>
                <assessment>Non-systematic Assessment</assessment>
                <description>5 mm x 5 mm erythematous area underneath the chest patch applied during mucociliary clearance measurement</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="20"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Allison Burbank, MD</name_or_title>
      <organization>Center for Environmental Medicine, Asthma and Lung Biology; University of North Carolina, Chapel Hill</organization>
      <phone>919-843-2714</phone>
      <email>allison_burbank@med.unc.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

